Witjes - Figure 10
Intravesical Chemotherapy
FIG. 10: BCG is included, of course, in treatment recommendations for the intermediate-risk group.[1,2] However, intravesical chemotherapy is a realistic alternative, and it certainly has fewer side effects than BCG. In cases of doubt about what to do with patients in this intermediate-risk group, they can be subclassified into the higher and lower ends of intermediate risk.
References
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer; unabridged version: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Linthicum, MD: American Urological Association; 2016 https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf Accessed August 3, 2017.
Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447−61 http://dx.doi.org/10.1016/j.eururo.2016.05.041
